Implementation of Mobile Medication Units: Findings from a Qualitative Study

In light of the continuing opioid epidemic in the United States, DEA lifted a moratorium on approvals of new mobile medication units (MMUs) to increase access to OTPs. The new DEA guidance also authorized OTPs to add a “mobile component” to their existing registration, eliminating the separate registration requirement for MMUs. To better understand the current state of MMU implementation since these changes were implemented, the Office of the Assistance Secretary for Planning and Evaluation commissioned this study, which included an environmental scan and key informant interviews with policy experts and people with first-hand experience implementing MMUs.

This research was compiled or funded by HHS/ASPE’s Office of Behavioral Health, Disability, and Aging Policy (BHDAP). Additional research in this area is available at the ASPE Behavioral Health page.

*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to POC Name, brenda.veazey@hhs.gov. Content will be updated pending the outcome of the Section 508 review.

Available Report:

• Implementation of Mobile Medication Units: Findings from a Qualitative Study

Related Products:

• Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care (2020) [HTML version also available]